Anti-Human DR5 (Drozitumab)-APC
Catalogue Number: 12-8061-ABO
| Manufacturer: | Abeomics |
| Type: | Recombinant Monoclonal |
| Alias: | DR5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 50 ug |
| Host name: | Human |
| Clone: | PRO95780 |
| Isotype: | IgG1, lambda |
| Immunogen: | DR5 scFv |
| Application: | FA |
Description
Description: Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Drozitumab. Clone PRO95780 recognizes human death receptor 5 (DR5). This product is for research use only. Drozitumab is a monoclonal antibody that specifically binds to human DR5. DR5 is expressed in a variety of solid tumors and hematologic malignancies, which are characteristically resistant to apoptosis. Drozitumab is a proapoptotic receptor agonists (PARA) that induces apoptosis in a variety of human cancer cell lines and xenograft models, both alone and in tandem with other antineoplastic agents.1 Apoptosis of cancer cells triggered by the activation of DR5, occurs without affecting most normal cell types. Anti-Human DR5 (Drozitumab) utilizes the same variable regions from the therapeutic antibody Drozitumab making it ideal for research projects.
Additional Text
Antibody Clonality
Monoclonal
Application Notes
The suggested concentration for Drozitumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
Storage Note
This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.
12-8061 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations